Abstract
Purpose: We studied EGFR mutations in circulating tumor DNA (ctDNA) and explored their role in predicting the progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients treated with erlotinib or gefitinib. Methods: The L858R, T790M mutations and exon 19 deletions were quantified in plasma using digital droplet polymerase chain
... read more